Document is current
Any future updates will be listed below
-
Authors
Eirin, Alfonso
Thaler, Roman
Glasstetter, Logan M.
Xing, Li https://orcid.org/0000-0003-0183-8000
Zhu, Xiang-Yang
Osborne, Andrew C.
Mondesir, Ronscardy
Bhagwate, Aditya V.
Lerman, Amir https://orcid.org/0000-0002-9446-5313
van Wijnen, Andre J. https://orcid.org/0000-0002-4458-0946
Lerman, Lilach O. https://orcid.org/0000-0002-3271-3887
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL158691, DK120292, DK122734, AG062104, DK129240)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
- License Information
-
More Information
Article History
Received: 30 August 2023
Revised: 22 May 2024
Accepted: 24 May 2024
First Online: 1 June 2024
Competing interests
: LOL is an advisor to CureSpec and Ribocure Pharmaceuticals. The remaining authors declare no conflicts of interest.
: This study was approved by the Institutional Review Board of the Mayo Clinic (Approval Number: 18-005076).
